血清标志物联合影像学在乳腺癌早期诊断中的价值分析

Abstract: Objective To explore the clinical value of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) combined with serum tumor markers: carbohydrate antigen 153 (CA153) and carcinoembryonic antigen (CEA) in the diagnosis of breast cancer. Methods A total of 90 patients with space-occupying breast lesions admitted to our hospital from September 2021 to September 2024 were included. They were divided into the breast cancer group and the benign group based on the pathological analysis results. Among them, there were 60 patients in the breast cancer group and 30 patients in the benign group. All patients underwent combined (DCE-MRI, serum CA153, CEA) tests. Combining the differences in the main imaging features of CEA, CA153 and magnetic resonance imaging (MRI) between the two groups, the application value of CEA combined with CA153 detection was evaluated. Meanwhile, the differences in the imaging features of DCE-MRI, serum CA153 and CEA in patients with different clinical stages were analyzed. Results The levels of serum CA153 and CEA in the breast cancer group were significantly higher than those in the benign group, and the difference was statistically significant (P＜0.05). The main imaging manifestations on DCE-MRI in the breast cancer group was higher than that in the benign group which was statistically significant (P＜0.05). The sensitivity of the combined detection of CA153 and CEA was 80.00%, the specificity was 78.95%, the accuracy was 79.59%, and the AUC was 0.851. The levels of CA153 and CEA and the manifestations of malignant MRI images in the stage III～IV group of breast cancer patients were significantly better than those in the stage I～II group, and the difference was statistically significant (P＜0.05). The sensitivity, specificity and accuracy of the combined diagnosis of MRI+CA153+CEA were significantly higher than those of MRI alone and the combined diagnosis of CA153+CEA (P＜0.05). The enhanced curve of rapid entry and exit, irregular boundaries, and associated lymph node enlargement in the stage III～IV group of breast cancer patients were significantly higher than those in the stage I～II group, and the difference was statistically significant (P＜0.05). Conclusion In clinical practice, the combined detection of breast DCE-MRI with serum CA153 and CEA can significantly improve the diagnostic accuracy of breast cancer. In addition, the levels of CA153 and CEA, as well as some typical imaging manifestations of MRI, are closely related to the stage of breast cancer. Therefore, the detection of these indicators can help doctors determine the development stage of breast cancer and its tumors, thereby providing a more reliable basis for subsequent treatment.